Log in or Sign up for Free to view tailored content for your specialty!
Sjögren’s Syndrome News
‘Underdiagnosed and undertreated’: Recognizing World Sjögren’s Day
Dry eye in Sjögren’s syndrome remains “underdiagnosed and undertreated,” and often not fully understood, according to Sjögren Europe, which is gearing up for World Sjögren’s Day on July 23 with a campaign aimed at raising awareness online.
Selexipag improves outcomes in PAH-associated connective tissue disease in real-world study
SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.
Log in or Sign up for Free to view tailored content for your specialty!
Sjögren’s syndrome ‘not curable, but certainly treatable’ with available therapies
DESTIN, Fla. — Although not currently curable, the symptoms of Sjögren’s syndrome, like dry eyes and dry mouth, can be effectively managed using a variety of therapies, said a speaker said at the Congress of Clinical Rheumatology East 2022 meeting.
'Oft-neglected' Sjögren's syndrome now second most common autoimmune disease
DESTIN, Fla. — Myriad symptoms and three different sets of classification criteria make Sjögren's syndrome a challenging diagnosis, according to a presenter at the Congress of Clinical Rheumatology East.
STAR aims to be ‘gold standard’ for outcome measures in Sjögren’s syndrome
The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers.
Sjögren’s Foundation shares patient stories for awareness month
Impacting roughly 1 million to 4 million Americans, Sjögren’s syndrome is estimated to be one of the most common autoimmune diseases in the United States, according to the Sjögren’s Foundation.
Rilzabrutinib active, safe in immune thrombocytopenia
Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.
‘Stronger together’: Rheumatology groups build community for Autoimmune Awareness Month
March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.
Nintedanib slows FVC decline in autoimmune-related interstitial lung disease
Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.
'Waste of energy': One-third of connective tissue disease RCTs never completed, published
One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read